Hodgkin Lymphoma Across the Age Spectrum: Epidemiology, Therapy, and Late Effects

Seminars in Radiation Oncology

Volumn 20, Issue 1, 2010, Pages 30-44

  Punnett, Angela ^a   Tsang, Richard W ^b   Hodgson, David C ^b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; GALLIUM 67; METHOTREXATE; MITOXANTRONE; PREDNISOLONE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

AGE; BONE MARROW TOXICITY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER RISK; CANCER SURVIVAL; CANCER THERAPY; CARDIOTOXICITY; CLINICAL EVALUATION; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DOSE RESPONSE; DRUG DOSE ESCALATION; GERIATRIC PATIENT; HEART FAILURE; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; LYMPHOCYTE DEPLETION HODGKIN LYMPHOMA; METASTASIS; MIXED CELLULARITY HODGKIN LYMPHOMA; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; NODULAR SCLEROSIS HODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; THERAPY EFFECT; THYROID DISEASE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGING; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; RADIATION DOSAGE; RISK FACTORS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 70549085159     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semradonc.2009.09.006     Document Type: Review

References (135)

1. Brenner H., Gondos A., and Pulte D. Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patients. Blood 111 (2008) 2977-2983
2. Donaldson S.S., and Kaplan H.S. Complications of treatment of Hodgkin's disease in children. Cancer Treat Rep 66 (1982) 977-989
3. Mauch P.M., Weinstein H., and Botnick L. An evaluation of long-term survival and treatment complications in children with Hodgkin's disease. Cancer 51 (1983) 925-932
4. Ferme C., Eghbali H., and Meerwaldt J.H. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med 357 (2007) 1916-1927
5. Ries L.A.G., Eisner M.P., and Kosary C.L. SEER cancer statistics review, 1975-2002. http://seer.cancer.gov/csr/1975_2002/
6. Armstrong A.A., Alexander F.E., and Cartwright R. Epstein-Barr virus and Hodgkin's disease: Further evidence for the three disease hypothesis. Leukemia 12 (1998) 1272-1276
7. Andersson J. Epstein-Barr virus and Hodgkin's lymphoma. Herpes 13 (2006) 12-16
8. Jarrett R.F. Viruses and Hodgkin's lymphoma. Ann Oncol 13 suppl 1 (2002) 23-29
9. Grufferman S., and Delzell E. Epidemiology of Hodgkin's disease. Epidemiol Rev 6 (1984) 76-106
10. Spitz M.R., Sider J.G., and Johnson C.C. Ethnic patterns of Hodgkin's disease incidence among children and adolescents in the United States, 1973-82. J Natl Cancer Inst 76 (1986) 235-239
11. Cleary S.F., Link M.P., and Donaldson S.S. Hodgkin's disease in the very young. Int J Radiat Oncol Biol Phys 28 (1994) 77-83
12. Parkes S.E., Coad N.A., and Muir K.R. Hodgkin's disease in children in the West Midlands, 1957-86: A large population-based study. Pediatr Hematol Oncol 11 (1994) 471-486
13. Alexander F.E., Jarrett R.F., and Lawrence D. Risk factors for Hodgkin's disease by Epstein-Barr virus (EBV) status: Prior infection by EBV and other agents. Br J Cancer 82 (2000) 1117-1121
14. Glaser S.L., Lin R.J., and Stewart S.L. Epstein-Barr virus-associated Hodgkin's disease: Epidemiologic characteristics in international data. Int J Cancer 70 (1997) 375-382
15. Flavell K.J., Biddulph J.P., and Powell J.E. South Asian ethnicity and material deprivation increase the risk of Epstein-Barr virus infection in childhood Hodgkin's disease. Br J Cancer 85 (2001) 350-356
16. Westergaard T., Melbye M., and Pedersen J.B. Birth order, sibship size and risk of Hodgkin's disease in children and young adults: A population-based study of 31 million person-years. Int J Cancer 72 (1997) 977-981
17. Chang E.T., Zheng T., Weir E.G., et al. Childhood social environment and Hodgkin's lymphoma: New findings from a population-based case-control study. Cancer Epidemiol Biomarkers Prev 13 (2004) 1361-1370
18. Asano N., Yamamoto K., and Tamaru J. Age-related Epstein-Barr virus (EBV)-associated B-cell lymphoproliferative disorders: Comparison with EBV-positive classic Hodgkin lymphoma in elderly patients. Blood 113 (2009) 2629-2636
19. Engert A., Ballova V., and Haverkamp H. Hodgkin's lymphoma in elderly patients: A comprehensive retrospective analysis from the German Hodgkin's Study Group. J Clin Oncol 23 (2005) 5052-5060
20. MacMahon B. Epidemiology of Hodgkin's disease. Cancer Res 26 (1966) 1189-1201
21. Carbone A., and Gloghini A. AIDS-related lymphomas: From pathogenesis to pathology. Br J Haematol 130 (2005) 662-670
22. Bierman P.J., Vose J.M., and Langnas A.N. Hodgkin's disease following solid organ transplantation. Ann Oncol 7 (1996) 265-270
23. Rowlings P.A., Curtis R.E., and Passweg J.R. Increased incidence of Hodgkin's disease after allogeneic bone marrow transplantation. J Clin Oncol 17 (1999) 3122-3127
24. Smitten A.L., Simon T.A., and Hochberg M.C. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther 10 (2008) R45
25. Landgren O., Engels E.A., and Pfeiffer R.M. Autoimmunity and susceptibility to Hodgkin lymphoma: A population-based case-control study in Scandinavia. J Natl Cancer Inst 98 (2006) 1321-1330
26. Goldin L.R., Pfeiffer R.M., and Gridley G. Familial aggregation of Hodgkin lymphoma and related tumors. Cancer 100 (2004) 1902-1908
27. Lister T.A., Crowther D., and Sutcliffe S.B. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 7 (1989) 1630-1636
28. Ng A.K., Bernardo M.V., and Silver B. Mid- and post-ABVD gallium scanning predicts for recurrence in early-stage Hodgkin's disease. Int J Radiat Oncol Biol Phys 61 (2005) 175-184
29. Wirth A., Seymour J.F., and Hicks R.J. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. Am J Med 112 (2002) 262-268
30. Van Den Bossche B., Lambert B., and De Winter F. 18FDG PET versus high-dose 67Ga scintigraphy for restaging and treatment follow-up of lymphoma patients. Nucl Med Commun 23 (2002) 1079-1083
31. Smith R.S., Chen Q., and Hudson M.M. Prognostic factors for children with Hodgkin's disease treated with combined-modality therapy. J Clin Oncol 21 (2003) 2026-2033
32. Hasenclever D., and Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 339 (1998) 1506-1514
33. Bayle-Weisgerber C., Lemercier N., and Teillet F. Hodgkin's disease in children. Results of therapy in a mixed group of 178 clinical and pathologically staged patients over 13 years. Cancer 54 (1984) 215-222
34. Gehan E.A., Sullivan M.P., and Fuller L.M. The intergroup Hodgkin's disease in children. A study of stages I and II. Cancer 65 (1990) 1429-1437
35. Donaldson S.S., Glatstein E., and Rosenberg S.A. Pediatric Hodgkin's disease. II. Results of therapy. Cancer 37 (1976) 2436-2447
36. Devita Jr. V.T., Serpick A.A., and Carbone P.P. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med 73 (1970) 881-895
37. Longo D.L., Young R.C., and Wesley M. Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 4 (1986) 1295-1306
38. Donaldson S.S., and Link M.P. Combined modality treatment with low-dose radiation and MOPP chemotherapy for children with Hodgkin's disease. J Clin Oncol 5 (1987) 742-749
39. Jenkin D., Doyle J., and Berry M. Hodgkin's disease in children: Treatment with MOPP and low-dose, extended field irradiation without laparotomy. Late results and toxicity. Med Pediatr Oncol 18 (1990) 265-272
40. Oberlin O., Leverger G., and Pacquement H. Low-dose radiation therapy and reduced chemotherapy in childhood Hodgkin's disease: The experience of the French Society of Pediatric Oncology. J Clin Oncol 10 (1992) 1602-1608
41. Bonadonna G., Zucali R., and Monfardini S. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 36 (1975) 252-259
42. Canellos G.P., Anderson J.R., and Propert K.J. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327 (1992) 1478-1484
43. Duggan D.B., Petroni G.R., and Johnson J.L. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: Report of an intergroup trial. J Clin Oncol 21 (2003) 607-614
44. Santoro A., Bonadonna G., and Valagussa P. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: Superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 5 (1987) 27-37
45. NCCN: The NCCN clinical practice guidelines in oncology. Hodgkin's Disease/Lymphoma. http://www.nccn.org
46. Engert A., and Dreyling M. Hodgkin's lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 19 suppl 2 (2008) ii65-ii66
47. Press O.W., LeBlanc M., and Lichter A.S. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. J Clin Oncol 19 (2001) 4238-4244
48. Raemaekers J., Kluin-Nelemans H., Teodorovic I., et al. The achievements of the EORTC Lymphoma Group. European Organisation for Research and Treatment of Cancer. Eur J Cancer 38 suppl 4 (2002) S107-S113
49. Diehl V., and Fuchs M. Early, intermediate and advanced Hodgkin's lymphoma: Modern treatment strategies. Ann Oncol 18 suppl 9 (2007) ix71-ix79
50. Landman-Parker J., Pacquement H., and Leblanc T. Localized childhood Hodgkin's disease: Response-adapted chemotherapy with etoposide, bleomycin, vinblastine, and prednisone before low-dose radiation therapy-results of the French Society of Pediatric Oncology Study MDH90. J Clin Oncol 18 (2000) 1500-1507
51. Donaldson S.S., Link M.P., and Weinstein H.J. Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin's disease. J Clin Oncol 25 (2007) 332-337
52. Nachman J.B., Sposto R., and Herzog P. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol 20 (2002) 3765-3771
53. Schellong G., Potter R., and Bramswig J. High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: The German-Austrian multicenter trial DAL-HD-90. The German-Austrian Pediatric Hodgkin's Disease Study Group. J Clin Oncol 17 (1999) 3736-3744
54. Dorffel W., Luders H., and Ruhl U. Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin's disease in children and adolescents: Analysis and outlook. Klin Padiatr 215 (2003) 139-145
55. Engert A., Schiller P., and Josting A. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: Results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 21 (2003) 3601-3608
56. Bonadonna G., Bonfante V., and Viviani S. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: Long-term results. J Clin Oncol 22 (2004) 2835-2841
57. Eich H., Mueller R., and Engert A. Comparison of 30 Gy versus 20 Gy involved field radiotherapy after two versus four cycles of ABVD in early stage Hodgkin's lymphoma: Interim analysis of the German Hodgkin Study Group Trial HD10. Int J Radiat Oncol Biol Phys 63 suppl 1 (2005) S1
58. Hodgson D.C., Hudson M.M., and Constine L.S. Pediatric Hodgkin lymphoma: Maximizing efficacy and minimizing toxicity. Semin Radiat Oncol 17 (2007) 230-242
59. Tebbi C.K., Mendenhall N., and London W.B. Treatment of stage I, IIA, IIIA(1) pediatric Hodgkin's disease with doxorubicin, bleomycin, vincristine and etoposide (DBVE) and radiation: A Pediatric Oncology Group (POG) study. Pediatr Blood Cancer 46 (2006) 198-202
60. Meyer R.M. Is there convincing evidence for the use of chemotherapy alone in patients with limited stage Hodgkin's lymphoma?. Eur J Haematol Suppl 66 (2005) 115-120
61. Yahalom J. Don't throw out the baby with the bathwater: On optimizing cure and reducing toxicity in Hodgkin's lymphoma. J Clin Oncol 24 (2006) 544-548
62. Meyer R.M., Gospodarowicz M.K., and Connors J.M. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 23 (2005) 4634-4642
63. Thomas J., Ferme C., and Noordijk E.M. Results of the EORTC-GELA H9 randomized trials: The H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin's lymphoma. Haematologica 92 (2007) 27
64. Noordijk E.M., Carde P., Dupouy N., et al. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: Long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Cin Oncol 24 (2006) 3128-3135
65. Gobbi P.G., Levis A., and Chisesi T. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: Final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol 23 (2005) 9198-9207
66. Aleman B.M., Raemaekers J.M., and Tirelli U. Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med 348 (2003) 2396-2406
67. Aleman B.M., van den Belt-Dusebout A.W., Klokman W.J., et al. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 21 (2003) 3431-3439
68. Ferme C., Mounier N., Casasnovas O., et al. Long-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: A study by the Groupe d'Etude des Lymphomes de 1'Adulte (GELA). Blood 107 (2006) 4635-4642
69. Diehl V., Franklin J., and Pfreundschuh M. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 348 (2003) 2386-2395
70. Diehl V., Schiller P., and Engert A. Results of the Third Interim Analysis of the HD12 Trial of the GHSG: 8 courses of escalated BEACOPP versus 4 escalated and 4 baseline courses of BEACOPP with or without additive radiotherapy for Advanced Stage Hodgkin's Lymphoma [abstract]. Blood 102 (2003) 85
71. Diehl V., Haverkamp H., Mueller R.P., et al. Eight cycles of BEACOPP Escalated compared with 4 cycles of BEACOPP Baseline with or without radiotherapy in patients with advanced stage Hodgkin Lymphoma (HL): Final analysis of the randomized HD12 trial of the German Hodgkin Study Group (GHSG). Blood (ASH Annual Meeting Abstracts) 112 (2008) 1558
72. Ruhl U., Albrecht M.R., Lueders H., et al. The German multinational GPOH-HD95 trial: Treatment results and analysis of failures in pediatric Hodgkins disease using combination chemotherapy with and without radiation. In J Radiat Oncol Biol Phys 60 (2004) S131
73. Weiner M.A., Leventhal B., and Brecher M.L. Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: A Pediatric Oncology Group study. J Clin Oncol 15 (1997) 2769-2779
74. Hudson M.M., Krasin M., and Link M.P. Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease. J Clin Oncol 22 (2004) 4541-4550
75. Cosset J.M., Ferme C., and Eghbali H. MOPP/ABV hybrid and irradiation in unfavourable supradiaphragmatic clinical stages I-II Hodgkin's lymphoma: Preliminary results of the EORTC-GELA H8-U randomized trial (# 20931) in 995 patients. Leuk Lymphoma 42 (2001) 12
76. Diehl V., Brillant C., and Engert A. Reduction of combined modality treatment intensity in early stage Hodgkin's lymphoma: Results of the fourth interim analysis of the HD 10 trial of the GHSG. Eur J Haematol 73 suppl 65 (2004) 37
77. Horning S.J., Hoppe R.T., and Breslin S. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: Mature results of a prospective clinical trial. J Clin Oncol 20 (2002) 630-637
78. Radford J.A., Rohatiner A.Z., and Ryder W.D. ChlVPP/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin's disease. J Clin Oncol 20 (2002) 2988-2994
79. Sieber M., Bredenfeld H., and Josting A. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: Results of a pilot study of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 21 (2003) 1734-1739
80. Ferme C., Sebban C., and Hennequin C. Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin's disease: Results of the groupe d'etudes des lymphomes de l'Adulte H89 trial. Blood 95 (2000) 2246-2252
81. Diehl V., Loeffler M., and Pfreundschuh M. Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advance Hodgkin's disease. German Hodgkins' Study Group (GHSG). Ann Oncol 6 (1995) 901-910
82. Loeffler M., Brosteanu O., and Hasenclever D. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. J Clin Oncol 16 (1998) 818-829
83. Fabian C.J., Mansfield C.M., and Dahlberg S. Low-dose involved field radiation after chemotherapy in advanced Hodgkin's disease. A Southwest Oncology Group randomized study. Ann Intern Med 120 (1994) 903-912
84. Eich H.T., Staar S., and Gossmann A. The HD12 panel of the German Hodgkin Lymphoma Study Group (GHSG): A quality assurance program based on a multidisciplinary panel reviewing all patients' imaging. Am J Clin Oncol 27 (2004) 279-284
85. Schwartz C.L. Special issues in pediatric Hodgkin's disease. Eur J Haematol Suppl 66 (2005) 55-62
86. Dann E.J., Bar-Shalom R., and Tamir A. Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Blood 109 (2007) 905-909
87. Kelly K.M., Hutchinson R.J., and Sposto R. Feasibility of upfront dose-intensive chemotherapy in children with advanced-stage Hodgkin's lymphoma: Preliminary results from the Children's Cancer Group Study CCG-59704. Ann Oncol 13 suppl 1 (2002) 107-111
88. Advani R., Maeda L., and Lavori P. Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease. J Clin Oncol 25 (2007) 3902-3907
89. Guay C., Lepine M., and Verreault J. Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation. J Nucl Med 44 (2003) 1225-1231
90. Naumann R., Vaic A., and Beuthien-Baumann B. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br J Haematol 115 (2001) 793-800
91. de Wit M., Bohuslavizki K.H., and Buchert R. 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. Ann Oncol 12 (2001) 29-37
92. Hutchings M., Loft A., and Hansen M. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107 (2006) 52-59
93. Gallamini A., Rigacci L., and Merli F. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica 91 (2006) 475-481
94. Gallamini A., Hutchings M., and Rigacci L. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: A report from a joint Italian-Danish study. J Clin Oncol 25 (2007) 3746-3752
95. Picardi M., De Renzo A., and Pane F. Randomized comparison of consolidation radiation versus observation in bulky Hodgkin's lymphoma with post-chemotherapy negative positron emission tomography scans. Leuk Lymphoma 48 (2007) 1721-1727
96. Kaplan H.S., and Rosenberg S.A. The treatment of Hodgkin's disease. Med Clin North Am 50 (1966) 1591-1610
97. Girinsky T., van der Maazen R., and Specht L. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: Concepts and guidelines. Radiother Oncol 79 (2006) 270-277
98. Shahidi M., Kamangari N., and Ashley S. Site of relapse after chemotherapy alone for stage I and II Hodgkin's disease. Radiother Oncol 78 (2006) 1-5
99. Campbell B.A., Voss N., and Pickles T. Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: A question of field size. J Clin Oncol 26 (2008) 5170-5174
100. Tirelli U., Serraino D., and Zagonel V. Hodgkin's disease in patients 70 years of age or more. A retrospective EORTC Lymphoma Group Study. Cancer Invest 8 (1990) 643-644
101. Klimm B., Diehl V., and Engert A. Hodgkin's lymphoma in the elderly: A different disease in patients over 60. Oncology (Williston Park) 21 (2007) 982-990 discussion 990, 996, 998, passim
102. Stats NCISEaERF. http://seer.cancer.gov/faststats/selections.php Accessed April 28, 2009
103. Ballova V., Ruffer J.U., and Haverkamp H. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol 16 (2005) 124-131
104. van Spronsen D.J., Janssen-Heijnen M.L., and Lemmens V.E. Independent prognostic effect of co-morbidity in lymphoma patients: Results of the population-based Eindhoven Cancer Registry. Eur J Cancer 41 (2005) 1051-1057
105. Kolstad A., Nome O., and Delabie J. Standard CHOP-21 as first line therapy for elderly patients with Hodgkin's lymphoma. Leuk Lymphoma 48 (2007) 570-576
106. Coiffier B. The challenges of Hodgkin lymphoma in the elderly. Oncology (Williston Park) 22 (2008) 1388,1393
107. Proctor S.J., Wilkinson J., and Sieniawski M. Hodgkin lymphoma in the elderly: A clinical review of treatment and outcome, past, present and future. Crit Rev Oncol Hematol 71 (2009) 222-232
108. Levis A., Anselmo A.P., and Ambrosetti A. Survival after Hodgkin lymphoma: Causes of death and excess mortality in patients treated in 8 consecutive trials. Cancer 115 (2009) 1680-1691
109. Favier O., Heutte N., Stamatoullas-Bastard A., et al. Survival after Hodgkin lymphoma: Causes of death and excess mortality in patients treated in 8 consecutive trials. Cancer 115 (2009) 1680-1691
110. Pihkala J., Saarinen U.M., and Lundstrom U. Myocardial function in children and adolescents after therapy with anthracyclines and chest irradiation. Eur J Cancer 32A (1996) 97-103
111. Polliack A. Late therapy-induced cardiac and pulmonary complications in cured patients with Hodgkin's disease treated with conventional combination chemoradiotherapy. Leuk Lymphoma 15 (1995) 7-10
112. Lipshultz S.E., Colan S.D., and Gelber R.D. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 324 (1991) 808-815
113. Kremer L.C., van Dalen E.C., and Offringa M. Frequency and risk factors of anthracycline-induced clinical heart failure in children: A systematic review. Ann Oncol 13 (2002) 503-512
114. Lipshultz S.E., Lipsitz S.R., and Mone S.M. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 332 (1995) 1738-1743
115. Donaldson S.S., Hudson M.M., and Lamborn K.R. VAMP and low-dose, involved-field radiation for children and adolescents with favorable, early-stage Hodgkin's disease: Results of a prospective clinical trial. J Clin Oncol 20 (2002) 3081-3087
116. Hodgson D.C., Gilbert E.S., and Dores G.M. Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J Clin Oncol 25 (2007) 1489-1497
117. Boice Jr. J.D. Radiation and breast carcinogenesis. Med Pediatr Oncol 36 (2001) 508-513
118. van Leeuwen F.E., Klokman W.J., and Stovall M. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 95 (2003) 971-980
119. Ralleigh G., and Given-Wilson R. Breast cancer risk and possible screening strategies for young women following supradiaphragmatic irradiation for Hodgkin's disease. Clin Radiol 59 (2004) 647-650
120. US Preventive Services Task Force. Screening for colorectal cancer: Recommendation and rationale. Ann Intern Med 137 (2002) 129-131
121. Landier W. Children's Oncology Group Long-Term Follow-Up Program Resource Guide. Children's Oncology Group (2007)
122. Travis L.B., Hill D., and Dores G.M. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst 97 (2005) 1428-1437
123. Bhatia S., Yasui Y., and Robison L.L. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: Report from the Late Effects Study Group. J Clin Oncol 21 (2003) 4386-4394
124. Constine L.S., Donaldson S.S., and McDougall I.R. Thyroid dysfunction after radiotherapy in children with Hodgkin's disease. Cancer 53 (1984) 878-883
125. Sklar C., Whitton J., and Mertens A. Abnormalities of the thyroid in survivors of Hodgkin's disease: Data from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab 85 (2000) 3227-3232
126. de Bruin J.P., Dorland M., and Spek E.R. Age-related changes in the ultrastructure of the resting follicle pool in human ovaries. Biol Reprod 70 (2004) 419-424
127. Ortin T.T., Shostak C.A., and Donaldson S.S. Gonadal status and reproductive function following treatment for Hodgkin's disease in childhood: The Stanford experience. Int J Radiat Oncol Biol Phys 19 (1990) 873-880
128. van den Berg H., Furstner F., and van den Bos C. Decreasing the number of MOPP courses reduces gonadal damage in survivors of childhood Hodgkin's disease. Pediatr Blood Cancer 42 (2004) 210-215
129. Bramswig J.H., Heimes U., and Heiermann E. The effects of different cumulative doses of chemotherapy on testicular function. Results in 75 patients treated for Hodgkin's disease during childhood or adolescence. Cancer 65 (1990) 1298-1302
130. Hobbie W.L., Ginsberg J.P., and Ogle S.K. Fertility in males treated for Hodgkin's disease with COPP/ABV hybrid. Pediatr Blood Cancer 44 (2005) 193-196
131. Haukvik U.K., Dieset I., and Bjoro T. Treatment-related premature ovarian failure as a long-term complication after Hodgkin's lymphoma. Ann Oncol 17 (2006) 1428-1433
132. Bonadonna G., Santoro A., and Viviani S. Gonadal damage in Hodgkin's disease from cancer chemotherapeutic regimens. Arch Toxicol Suppl 7 (1984) 140-145
133. Behringer K., Breuer K., and Reineke T. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: A report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol 23 (2005) 7555-7564
134. Brusamolino E., Baio A., and Orlandi E. Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin's lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: A single-institution 15-year follow-up. Clin Cancer Res 12 (2006) 6487-6493
135. Hodgson D.C., Pintilie M., and Gitterman L. Fertility among female Hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapy. Hematol Oncol 25 (2007) 11-15